Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: A prospective controlled study

Surgery

Volumn 150, Issue 6, 2011, Pages 1250-1257

  Sugitani, Iwao ^a   Fujimoto, Yoshihide ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; THYROTROPIN;

ADULT; AGED; ARTICLE; BONE DENSITY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DETERIORATION; DISEASE FREE SURVIVAL; FEMALE; HORMONE INHIBITION; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MORNING DOSAGE; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THYROID PAPILLARY CARCINOMA; THYROTROPIN BLOOD LEVEL;

ADULT; AGED; BONE DENSITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; THYROXINE;

EID: 82755164560     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2011.09.013     Document Type: Article

References (23)

1. D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, and S.J. Mandel Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer Thyroid 19 2009 1167 1214
2. F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J.W. Smit, and W. Wiersinga European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium Eur J Endocrinol 154 2006 787 803 (Pubitemid 43997716)
3. K.A. Heemstra, N.A.T. Hamdy, J.A. Romijn, and J.W.A. Smit The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma Thyroid 16 2006 583 591 (Pubitemid 44066265)
4. I. Sugitani, and Y. Fujimoto Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial J Clin Endocrinol Metab 95 2010 4576 4583
5. T.P. Dunhill The surgery of the thyroid gland: the Lettsomian lectures Trans Med Soc Lond 60 1937 234 282
6. E.L. Mazzaferri, R.L. Young, J.F. Oertel, W.T. Kemmerer, and C.P. Page Papillary thyroid carcinoma: the impact of therapy in 576 patients Medicine 56 1977 171 196 (Pubitemid 8111452)
7. N.J. McGriff, G. Csako, L. Gourgiotis, L.C. Guthrie, F. Pucino, and N.J. Sarlis Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer Ann Med 34 2002 554 564 (Pubitemid 36113813)
8. D.S. Ross, R.M. Neer, E.C. Ridgway, and G.H. Daniels Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with l-thyroxine Am J Med 82 1987 1167 1170
9. J.A. Franklyn, J. Betteridge, J. Daykin, R. Holder, G.D. Oates, and J.V. Parle Long-term thyroxine treatment and bone mineral density Lancet 340 1992 9 13
10. A.W.C. Kung, T. Lorenz, and S.C.F. Tam Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women Clin Endocrinol 39 1993 535 540 (Pubitemid 23323950)
11. C.G. Müller, A. Bayley, J.E. Harrison, and R. Tsang Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance Thyroid 5 1995 81 87
12. A.W. Kung, and S.S. Yeung Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin J Clin Endocrinol Metab 81 1996 1232 1236 (Pubitemid 26083997)
13. B. Uzzan, J. Campos, M. Cucherat, P. Nony, J.P. Boissel, and G.Y. Perret Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis J Clin Endocrinol Metab 81 1996 4278 4289 (Pubitemid 26412030)
14. E. Jódar, L.M. Begoña, L. Garcia, D. Rigopoulou, G. Martínez, and F. Hawkins Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass Osteoporos Int 8 1998 311 316 (Pubitemid 28418264)
15. G. Grimnes, N. Emaus, R.M. Joakimsen, Y. Figenschau, and R. Jorde The relationship between serum TSH and bone mineral density in men and postmenopausal women: the Tromsø study Thyroid 18 2008 1147 1155
16. M.L. Quan, J. Pasieka, and O. Rorstad Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature J Surg Oncol 79 2002 62 70
17. B. Ongphiphadhanakul, S. Alex, L.E. Braverman, and D.T. Baran Excessive l-thyroxine therapy decreases femoral bone mineral densities in the male rat: effect of hypogonadism and calcitonin J Bone Miner Res 7 1992 1227 1231
18. D.S. Cooper, B. Specker, M. Ho, M. Sperling, P.W. Ladenson, and D.S. Ross Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry Thyroid 8 1998 737 744 (Pubitemid 28535681)
19. J. Jonklaas, N.J. Sarlis, D. Litofsky, K.B. Ain, S.T. Bigos, and J.D. Brierley Outcomes of patients with differentiated thyroid carcinoma following initial therapy Thyroid 16 2006 1229 1242 (Pubitemid 46080167)
20. I. Sugitani, N. Kasai, Y. Fujimoto, and A. Yanagisawa A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period Surgery 135 2004 139 148 (Pubitemid 38130764)
21. I. Sugitani, and Y. Fujimoto Management of low-risk papillary thyroid carcinoma: unique conventional policy in Japan and our efforts to improve the level of evidence Surg Today 40 2010 199 215
22. B. Biondi, and D.S. Cooper Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer Thyroid 20 2010 135 146
23. H.N. Rosen, A.C. Moses, J. Garber, D.S. Ross, S.L. Lee, and L. Ferguson Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate J Clin Endocrinol Metab 83 1998 2324 2330 (Pubitemid 28503022)